As shown in Figure 2, the overall survival ratios at 1, 3, and 5 years were 69.0%, 47.1%, and 31.2%, respectively, for HCC patients in the H-CA125 group and 88.3%, 70.1%, and 53.1%, respectively, for HCC patients in the N-CA125 group (p <0.0001, Figure 2A). Here, MUC16 is linked to hepatocellular carcinoma.